News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|December 23, 2024

Lp(a) in ASCVD and Guideline Recommendations

Episodes in this series

EP. 1 Lp(a) in ASCVD and Guideline Recommendations

EP. 1 Lp(a) in ASCVD and Guideline Recommendations

EP. 2 Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis

EP. 2 Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis

EP. 3 The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis

EP. 3 The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis

EP. 4 Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease

EP. 4 Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease

EP. 5 Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime

EP. 5 Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime

EP. 6 How the Genetic Nature of Lp(a) Levels Influences Screening

EP. 6 How the Genetic Nature of Lp(a) Levels Influences Screening

EP. 7 A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk

EP. 7 A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk

EP. 8 The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations

EP. 8 The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations

EP. 9 Evidence Supporting 2024 Guidance for Lp(a) Testing

EP. 9 Evidence Supporting 2024 Guidance for Lp(a) Testing

EP. 10 Factoring Cost, Recommendations, and Evidence Into Formulary Decisions about Lp(a) Testing

EP. 10 Factoring Cost, Recommendations, and Evidence Into Formulary Decisions about Lp(a) Testing

EP. 11 Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing

EP. 11 Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing

EP. 12 FDA-Approved and Pipeline Treatments for Elevated Lp(a) Levels

EP. 12 FDA-Approved and Pipeline Treatments for Elevated Lp(a) Levels

EP. 13 The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies

EP. 13 The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies

EP. 14 Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment

EP. 14 Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment

EP. 15 Lp(a) Testing: Prevalence and Strategies to Improve Uptake

EP. 15 Lp(a) Testing: Prevalence and Strategies to Improve Uptake

EP. 16 Implementing Lp(a) Testing in Health Systems: Lessons From Real-World Experience

EP. 16 Implementing Lp(a) Testing in Health Systems: Lessons From Real-World Experience

EP. 17 Implementing Lp(a) Testing: Learning From LDL Testing and Considering Value-Based Care Models

EP. 17 Implementing Lp(a) Testing: Learning From LDL Testing and Considering Value-Based Care Models

EP. 18 Present and Looking to the Future: Lp(a) Testing and Atherosclerotic Disease Management

EP. 18 Present and Looking to the Future: Lp(a) Testing and Atherosclerotic Disease Management

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

Moderna, Merck mRNA Cancer Vaccine Succeeds in Late-Stage Trial

County-Level CRC Mortality Disparities Linked to Broadband Gaps, Smoking, and Rurality

Monitoring Disease Progression and Liver Cancer Risk in Hepatitis B

Quantitative HBsAg Testing and the Path to Finite-Duration Therapy

Setting Clear Goals and Acting on Them: A Framework for RA Treatment Sequencing